Ghany MG, Pan CQ, Lok AS, et al. AASLD-ISDA practice guideline on treatment of chronic hepatitis B. Hepatology. 2025;83(4):974-997. PubMed 41186418
Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599-2607. PubMed 26571066
Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373(27):2608-2617. PubMed 26575258
Asselah T, Lee SS, Yao BB, et al. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6). Lancet Gastroenterol Hepatol. 2019;4(1):45-51. PubMed 30393106
US Preventive Services Task Force. Screening for hepatitis C virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement. JAMA. 2020;323(10):970-975. PubMed 32119076
Advisory Committee on Immunization Practices (ACIP). Recommended adult immunization schedule for adults aged 19 years or older, United States, 2023. Centers for Disease Control and Prevention. CDC Adult Immunization Schedule
Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352(26):2682-2695. PubMed 15987917
Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1 Suppl):S58-68. PubMed 25443346